Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
NCT ID: NCT00163501
Last Updated: 2016-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
600 participants
INTERVENTIONAL
2003-12-31
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
NCT00163514
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
NCT00659750
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
NCT00659841
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
NCT00163488
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
NCT00261287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciclesonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History and diagnosis of perennial allergic rhinitis by skin prick test
Exclusion Criteria
* A known hypersensitivity to any corticosteroid or any of the excipients in the formulation
* Use of any prohibited concomitant medications as defined by the study protocol
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca AstraZeneca
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
Encinitas, California, United States
Altana Pharma/Nycomed
Huntington Beach, California, United States
Altana Pharma/Nycomed
Long Beach, California, United States
Altana Pharma/Nycomed
Los Angeles, California, United States
Altana Pharma/Nycomed
Mission Viejo, California, United States
Altana Pharma/Nycomed
Newport Beach, California, United States
Altana Pharma/Nycomed
San Diego, California, United States
Altana Pharma/Nycomed
San Diego, California, United States
Altana Pharma/Nycomed
Stockton, California, United States
Altana Pharma/Nycomed
Vista, California, United States
Altana Pharma/Nycomed
Trumbull, Connecticut, United States
Altana Pharma/Nycomed
Clearwater, Florida, United States
Altana Pharma/Nycomed
DeLand, Florida, United States
Altana Pharma/Nycomed
Atlanta, Georgia, United States
Altana Pharma/Nycomed
Normal, Illinois, United States
Altana Pharma/Nycomed
Overland Park, Kansas, United States
Altana Pharma/Nycomed
New Orleans, Louisiana, United States
Altana Pharma/Nycomed
Bethesda, Maryland, United States
Altana Pharma/Nycomed
North Dartmouth, Massachusetts, United States
Altana Pharma/Nycomed
Forked River, New Jersey, United States
Altana Pharma/Nycomed
Skillman, New Jersey, United States
Altana Pharma/Nycomed
Springfield, New Jersey, United States
Altana Pharma/Nycomed
Liverpool, New York, United States
Altana Pharma/Nycomed
Raleigh, North Carolina, United States
Altana Pharma/Nycomed
Winston-Salem, North Carolina, United States
Altana Pharma/Nycomed
Cincinnati, Ohio, United States
Altana Pharma/Nycomed
Cincinnati, Ohio, United States
Altana Pharma/Nycomed
Oklahoma City, Oklahoma, United States
Altana Pharma/Nycomed
Portland, Oregon, United States
Altana Pharma/Nycomed
Easton, Pennsylvania, United States
Altana Pharma/Nycomed
Pittsburgh, Pennsylvania, United States
Altana Pharma/Nycomed
Cranston, Rhode Island, United States
Altana Pharma/Nycomed
Austin, Texas, United States
Altana Pharma/Nycomed
Dallas, Texas, United States
Altana Pharma/Nycomed
Houston, Texas, United States
Altana Pharma/Nycomed
Kerrville, Texas, United States
Altana Pharma/Nycomed
New Braunfels, Texas, United States
Altana Pharma/Nycomed
San Antonio, Texas, United States
Altana Pharma/Nycomed
Salt Lake City, Utah, United States
Altana Pharma/Nycomed
Richmond, Virginia, United States
Altana Pharma/Nycomed
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BY9010-M1-404-RDS-2005-12-11.pdf
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY9010/M1-404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.